急性缺血性卒中血管内治疗后个体化血压目标随机试验
多中心随机对照试验纳入440例前循环大血管闭塞且再灌注成功(mTICI≥2b)的急性缺血性卒中患者,比较再灌注分级导向的收缩压策略与指南推荐管理(收缩压<180 mmHg)。
要点
- 再灌注导向血压策略较指南管理提高90天良好功能结局(60.0% vs 47.1%)。
- 干预组出血转化更少(22.3% vs 31.6%,OR 0.62,95%CI 0.41-0.95)。
- 症状性颅内出血与90天死亡率两组无差异,支持个体化术后血压管理。
核心结论
- 在再灌注成功的急性缺血性卒中患者中,再灌注导向的血压策略改善功能结局并减少出血转化,且未增加重大安全事件。
研究设计与样本
- 研究者发起的多中心、前瞻性、随机、开放标签、盲法终点评估临床试验,在西班牙11家综合卒中中心进行。
- 纳入前循环大血管闭塞且血管内治疗后成功再灌注(mTICI评分≥2b)的成人患者,2021年6月14日至2025年10月1日入组,随访90天。
- 446例入组患者中440例纳入意向治疗分析(平均年龄75岁,53%为女性),6例因退出或撤回知情同意被排除。
- 按1:1随机分为再灌注导向收缩压策略组(mTICI 2b为140-160 mmHg;mTICI 2c/3为100-140 mmHg)与指南推荐管理组(收缩压<180 mmHg),持续72小时,按需使用降压药或升压药。
主要发现
- 出血转化干预组48例(22.3%)、对照组71例(31.6%),OR 0.62(95%CI 0.41-0.95)。
- 症状性颅内出血发生率3.5% vs 3.9%,90天死亡率15.4% vs 15.6%,两组无差异。
- 严重不良事件干预组34例(15.8%)、对照组27例(12.0%)。
关键数值与推荐
- 干预组收缩压目标:mTICI 2b为140-160 mmHg,mTICI 2c/3为100-140 mmHg,持续72小时。
- 对照组收缩压目标<180 mmHg,持续72小时。
- 主要结局为90天改良Rankin量表评分0-2分。
- 再灌注成功定义为mTICI评分≥2b。
临床怎么用
- 对血管内治疗再灌注成功的前循环大血管闭塞患者,可考虑按再灌注分级设定个体化收缩压目标而非统一宽松控制。
- mTICI 2b患者收缩压目标140-160 mmHg、mTICI 2c/3患者100-140 mmHg,持续72小时,或有助于改善功能结局并减少出血转化。
- 实施个体化血压目标时需按需使用降压药或升压药,并关注严重不良事件。
局限性
- 开放标签设计,仅终点评估采用盲法。
- 研究在西班牙11家中心进行,结果外推需谨慎。
- 随访期限为90天,缺乏更长期结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Optimal blood pressure (BP) management after successful endovascular therapy for acute ischemic stroke remains uncertain, as intensive lowering has shown no benefit or potential harm in prior trials. OBJECTIVE: To determine whether a reperfusion-guided systolic BP control strategy improves functional outcomes compared with guideline-recommended management after successful endovascular therapy for acute ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, multicenter, prospective, randomized, open-label clinical trial with blinded end point assessment was conducted among adults with acute ischemic stroke due to anterior circulation large-vessel occlusion who achieved successful reperfusion (modified Thrombolysis in Cerebral Infarction [mTICI] score ≥2b) after endovascular therapy at 11 comprehensive stroke centers in Spain between June 14, 2021, and October 1, 2025, with 90-day follow-up. Data analysis was conducted from February 1 to March 12, 2026. INTERVENTIONS: Participants were randomly assigned (1:1) to a reperfusion-guided systolic BP strategy (140-160 mm Hg for mTICI score of 2b; 100-140 mm Hg for mTICI score of 2c/3) or guideline-recommended management (systolic BP <180 mm Hg) for 72 hours using antihypertensive agents or vasopressors as needed. MAIN OUTCOMES AND MEASURES: The primary outcome was a favorable functional outcome, defined as a modified Rankin Scale score of 0 to 2 at 90 days, assessed in the intention-to-treat population. Of 446 enrolled patients, 440 were included in the intention-to-treat analysis (mean age, 75 years; 53% women); 6 were excluded due to withdrawal or consent withdrawal. RESULTS: Among 440 patients (mean [SD] age, 75 [12] years; 233 [53.0%] women), 215 were assigned to the intervention group and 225 to the control group. At 90 days, 129 patients (60.0%) in the intervention group and 106 (47.1%) in the control group achieved a favorable functional outcome (absolute risk difference, 13.3%; 95% CI, 4.1%-22.6%; P = .005). Hemorrhagic transformation occurred in 48 patients (22.3%) in the intervention group and 71 (31.6%) in the control group (odds ratio, 0.62; 95% CI, 0.41-0.95). The rates of symptomatic intracranial hemorrhage (3.5% vs 3.9%) and 90-day mortality (15.4% vs 15.6%) did not differ between groups. Serious adverse events occurred in 34 patients (15.8%) in the intervention group and 27 (12.0%) in the control group. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, a reperfusion-guided BP strategy improved functional outcomes and reduced hemorrhagic transformation without increasing major safety events, supporting a tailored approach to postthrombectomy BP management. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04892511.
引用
- Camps-Renom P, Guasch-Jiménez M, Álvarez-Cienfuegos J, et al. Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 42258192. doi:10.1001/jamaneurol.2026.1706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。